ABOUT POSSIBILITY OF THE USE OF AFOBAZOL FOR TREATMENT OF ALCOHOLIC CARDIOMYOPATHY AND PREVENTION OF ITS CONCOMITANT COMPLICATIONS

DOI: https://doi.org/None

S.A. Kryzhanovskii, I.B. Tsorin, L.G.Kolik, V.N. Stolyaruk, M.B. Vititnova, E.O. Ionova, A.V. Sorokina, I.A. Miroshkina, A.D. Durnev, S.B. Seredenin Research Zakusov Institute of Pharmacology, Baltiyskaya st., 8, Moscow, 125315, Russian Federation

The aim of the study. The proof of afobazole efficacy for treatment and prevention of alcoholic cardiomyopathy and attendant complications using the previously developed translational model. Materials and methods. Alcoholic cardiomyopathy was produced by continuous alcoholization of animals (10% ethanol) for 24 weeks. At the end of this period, the animals of the experimental group received afobazol (15 mg/kg/day, i.p.) for 28 days, and the animals of the control group – equivalent volume of isotonic sodium chloride solution. For evaluation of afobazole cardioprotective activity the complex of echocardiography, electrophysiological and morphological studies was used. Results. It was shown that systematic experimental therapy with afobazole promotes statistically significant (p≈0,004) increase of left ventricular ejection fraction of the heart, decrease of the area of the right and left ventricle caves of the heart. For example, the relative area of the left ventricle cava in animals treated by afobazol was more than in 2 times lower than in the control animals: 10,0±2,6 and 22,5±2,8% respectively (p≈0,001). Simultaneously a statistically significant (p≈0,0023) reduction of the number of animals with a fat inclusion into cardiomyocytes was observed, what indicates decreasing of the intensity of myocardial steatosis under the action of afobazole. In another series of experiments was show that, against the background of the systematic receiving of afobazole the threshold of electric fibrillation of ventricular was significantly higher (p≈0,009) than in the control animals, and it is almost matches that in the intact animals. Conclusion. In mature of alcoholic cardiomyopathy afobazole provides comprehensive cardioprotective effects, and this drug not only prevents the development of dilated heart failure and significantly reduces the intensity of the manifestations of fatty degeneration of the myocardium, but also restores the electrical stability of the myocardium almost back to normal condition and thus eliminates the risk of sudden cardiac death.
Keywords: 
alcoholic cardiomyopathy, translational model, rats, σ1-receptors, afobazole, cardioprotective effects, sudden cardiac death
Список литературы: 
  1. John U., Hanke M. Tobacco- and alcohol-attributable mortality and years of potential life lost in Germany. Eur. J. Public Health. 2003; 13 (3): 275–7.
  2. Mokdad A.H., Marks J.S., Stroup D.F., Gerberding J.L. Actual causes of death in the United States, 2000. JAMA. 2004; 291(10): 1238–45.
  3. Rehm J., Giesbrecht N., Patra J., Roerecke M. Estimating chronic disease deaths and hospitalizations due to alcohol use in Canada in 2002: implications for policy and preventon strategies. Prevent. Chronic Dis. 2006; 3 (4): A121.
  4. Balakrishnan R., Allender S., Scarborough P., Webster P., Rayner M. The burden of alcohol-related ill health in the United Kingdom. J. Public Health. 2009; 31 (3): 366–73.
  5. Bohan N.A., Mandel` A.I., Maksimenko N.N., Mihaleva L.D. Smertel`nye ishody pri alkogol`noy zavisimosti. Narkologiya. 2007; 12: 37–40. [Bockhan N.A., Mandel’ A.I., Maximenko N.N., Michaleva L.D. Deaths in alcohol dependence. Narkologija. 2007; 12: 37–40 (in Russian)]
  6. Nikitina S.Yu., Kozeeva G.M. Sovershenstvovanie statistiki smertnosti ot alkogolizma. Voprosy statistiki. 2006; 11: 21–3. [Nikitina S.Yu., Kozeeva G.M. Improving mortality statistics from alcoholism. Voprosy statistiki. 2006: 11: 21–3 (in Russian)]
  7. Semenova V.G., Antonova O.I., Evdokushkina G.N., Gavrilova N.S. Poteri naseleniya Rossii v 2000–2008 gg., obuslovlennye alkogolem: masshtaby, struktura, tendencii. Social`nye aspekty zdorov`ya naseleniya. 2010; 2: 34–7. Semenova VG., Antonova O.I., Evdokushkina G.N., Gavrilova N.S. The loss of the Russian population in 2000–2008 gg. caused by alcohol: the scale, structure, trends. Social’nye aspekty zdorov’ja naselenija. 2010; 2: 34–7 (in Russian)]
  8. Wannamethee G., Shaper A.G. Alcohol and sudden cardiac death. Br. Heart J. 1992; 68 (5): 443–8.
  9. Chazov E.I. Vnezapnaya smert`. 2013. http: // www. medicusamicus. com/ index. php?action=2x1229x1. [Chazov E.I. Sudden death. 2013. http: // www. medicusamicus. com/ index. php?action=2x1229x1]
  10. Vikhert A.M., Tsiplenkova V.G., Cherpachenko N.M. Alcoholic cardiomyopathy and sudden cardiac death. J. Am. Coll. Cardiol. 1986; 8 (Suppl. A.): 3A–11A.
  11. Rehm J., Zatonski W., Taylor B., Anderson P. Epidemiology and alcohol policy in Europe. Addiction. 2011; 106 (Suppl. 1): 11–9.
  12. Iacovoni A, De Maria R., Gavazzi A. Alcoholic cardiomyopathy. J. Cardiovasc. Med. 2010; 11 (12): 884–92.
  13. Permyakov A.V., Pirogov A.S., Yakimov I.A. Alkogol`naya kardiomiopatiya po dannym GUZ «BSME`» MZ UR (g. Izhevska) za 3 goda. Problemy e`kspertizy v medicine. 2003; 3 (2): 11–3. [Permyakova A.V., Pirogov A.C., Yakimov I.A. et al. Alcoholic cardiomyopsathy according GUZ «BSME» MZ UR (Izhevsk) for 3 years. Problemy jekspertizy v medicine. 2003; 3 (2): 11–3 (in Russian)]
  14. Klatsky A.L. Alcohol and cardiovascular health. Physiol. Behav. 2010; 100 (1): 76–81.
  15. Gordeeva M.V., Mitrofanova L.B., Pahomov A.V. i dr. Vnezapnaya serdechnaya smert` molodyh lyudey. Vestnik aritmologii. 2012; 68: 27–37. [Gordeeva M.V., Mitrofanova L.B., Pakhomov A.V. et al. Sudden cardiac death adolescents and young adult. Vestnik aritmologii. 2012; 68: 27–37 (in Russian)]
  16. Ivashkin V.T., Drapkina O.M., Ashihmin Ya.I. Alkogol`naya kardiomiopatiya. Medicinskaya pomoshh`: Nauchno-prakticheskiy zhurnal. 2006; 3: 11–5. [Ivashkin V.T., Drapkina O.M., Ashikhmin Ia.I. Alcoholic cardiomyopathy. Medicinskaja pomoshh’: Nauchno-prakticheskij zhurnal. 2006; 3: 11–5 (in Russian)]
  17. Seredenin S.B., Kryzhanovskiy S.A., Kolik L.G., Corin I.B., Stolyaruk V.N., Vititnova M.B., Ionova E.O., Sorokina A.V., Durnev A.D., Alekseev K.V. Agonist sigma-1 receptorov afobazol – novoe lekarstvennoe sredstvo dlya profilaktiki vnezapnoy serdechnoy smerti u pacientov, stradayushhih alkogol`noy kardiomiopatiey. Zayavka na patent RF № 2013150298 – 2013. [Seredenin S.B., Kryzhanovsky S.A., Kolik L.G., Tsorin I.B., Stolyaruk V.N., Vititnova M.B., Ionova E.O., Sorokina A.V., Durnev A.D., Alekseev K.V. Agonist sigma-1 receptor afobazol – a new medicament for the prevention of sudden cardiac death in patients suffering from alcoholic cardiomyopathy. Zajavka na patent RF № 2013150298 – 2013 (in Russian)]
  18. Kryzhanovskiy S.A., Sorokina A.V., Stolyaruk V.N., Vititnova M.B., Miroshkina I.A., Corin I.B., Durnev A.D., Seredenin S.B. Izuchenie antiishemicheskogo deystviya afobazola v usloviyah e`ksperimental`nogo infarkta miokarda. Byulleten` e`ksperim. biologii i mediciny. 2010; 150 (3): 284–7. [Kryzhanovskyi S.A., Sorokina A.V., Stolyaruk V.N., Vititnova M.B., Miroshkina I.A., Tsorin I.B., Durnev A.D., Seredenin S.B. Study of the anti-ischemic action of afobazole in experimental myocardial infarction. Bul. Exp. Biol. Med. 2010; 150 (3): 284–7 (in Russian)]
  19. Kryzhanovskiy S.A., Corin I.B., Sorokina A.V., Vititnova M.B., Stolyaruk V.N., Miroshkina I.A., Chichkanov G.G., Seredenin S.B. Kardioprotektivnye e`ffekty afobazola u zhivotnyh s hronicheskoy ishemiey miokarda. Molekulyarnaya medicina. 2013; 5: 37–42. [Kryzhanovsky S.A., Tsorin I.B., Sorokina A.V., Vititnova M.B., Stolyaruk V.N., Miroshkina I.A., Chichkanov G.G., Seredenin S.B. Cardioprotective effects of afobazol in animals with chronic myocardial ischemia. Molekuljarnaja medicina. 2013; 5: 37–42 (in Russian)]
  20. Stolyaruk V.N., Vititnova M.B., Corin I.B., Kryzhanovskiy S.A. Izuchenie protivofibrillyatornoy aktivnosti afobazola u zhivotnyh s intaktnym i denervirovannym miokardom. Vestnik RAMN. 2010; 4: 45–8. [Stolyaruk V.N., Vititnova M.B., Tsorin I.B., Kryzhanovskyi S.A. Investigation of afobasol antifibrillation activity in animals with intact and denervated myocardium. Vestnik RAMN. 2010; 4: 45–8 (in Russian)]
  21. Kryzhanovskiy S.A., Stolyaruk V.N., Vititnova M.B., Corin I.B., Seredenin S.B. K mehanizmu protivofibrillyatornogo deystviya «afobazola». Byulleten`. e`ksperim. biologii i mediciny. 2010; 149 (3): 290–3. [Kryzhanovskyi S.A., Stolyaruk V.N., Vititnova M.B., Tsorin I.B., Seredenin S.B. To the mechanism of afobazole antyfirillatory action. Bul. Exp. Biol. Med. 2010; 149 (3): 290–3 (in Russian)]
  22. Seredenin S.B., Corin I.B., Vititnova M.B., Stolyaruk V.N., Chichkanov G.G., Kryzhanovskiy S.A. K mehanizmu protivoishemicheskogo deystviya preparata «afobazol». Byulleten` e`ksperim. biologii i mediciny. 2013; 155 (6): 723–7. [Seredenin S.B., Tsorin I.B., Vititnova M.B., Stolyaruk V.N., Chichkanov G.G., Kryzhanovsky S.A. To mechanism of the antiischemic action of afobasol. 2013; 155 (6): 723–7 (in Russian)]
  23. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., Picard M.H., Roman M.J., Seward J., Shanewise J.S., Solomon S.D., Spencer K.T., Sutton M.S., Stewart W.J.; Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recomendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Camber Quantification Writing Group, developed in conjunction with European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 2005; 18: 1440–63.
  24. Kryzhanovskiy S.A., Kolik L.G., Corin I.B., Corin I.B., Ionova E.O., Stolyaruk V.N., Vititnova M.B., Nadorova A.V., Seredenin S.B. K vozmozhnosti ispol`zovaniya e`hokardiografii dlya ocenki e`tapov formirovaniya alkogol`noy kardiomiopatii. Fiziologiya cheloveka. 2014; 40 (1): 122–8. [Kryzhanovsky S.A., Kolik L.G., Tsorin I.B., Ionova E.O., Stolyaruk V.N., Vititnova M.B., Nadorova A.V., Seredenin S.B. To the potential use of alcocholic cardiomyopathy echocardiography assessment of forming. Human Physiology. 2014; 40 (1): 122–8 (in Russian)]
  25. Tereshhenko S.N., Zhirov I.V., Kotaeva E.A., Malichenko E.V. Alkogol`naya i dilatacionnaya kardiomiopatiya. Pravomochen li znak ravenstva? Kardiologiya. 2008; 3: 93–6. [Teresshenko V.G., Zhirov I.V., Kataeva E.A., Malichenko E.V. Alcoholic and dilated cardiomyopathy. Empowered to whether the sign of equality? Kardiologiia; 2008; 3: 93–6 (in Russian)]
  26. Fernández-Solà J., Nicolás J.M., Paré J.C. et al. Diastolic function impairment in alcoholics. Alcohol. Clin. Exp. Res. 2000; 24 (12): 1830–5.
  27. Santangeli P., Dello Russo A., Casella M., Pelargonio G., Di Biase L., Natale A. Left ventricular ejection fraction for the risk stratification of sudden cardiac death: friend or foe? Intern. Med. J. 2011; 41 (1a): 55–60.
  28. Drapkina O.M., Ashihmin Ya.I., Ivashkin V.T. Problema alkogol`noy kardiomiopatii. Vrach. 2005; 8: 48–50. [Drapkina O.M., Ashikhmin Ia.I., IvashkinV.T. The problem of alcoholic cardiomyopathy. Vrach. 2005; 8: 48–50 (in Russian)]
  29. Bogza M.V., Sorokina V.V., Konev V.P., Goloshubina V.V. Morfofunkcional`nye paralleli pri alkogol`noy kardiomiopatii v aspekte vnezapnoy smerti. Izvestiya vysshih uchebnyh zavedeniy. Povolzhskiy region. Medicinskie nauki. 2011; 2 (8): 19–24. [Bogza M.V., Sorokina V.V., Konev V.P., Golochubina V.V. Morphological and functional parallels with alcoholic cardiomyopathy in terms of sudden death. Izvestija vysshih uchebnyh zavedenij. Povolzhskij region. Medicinskie nauki. 2011; 2 (8): 19–24 (in Russian)]
  30. Erohin Yu.A., Hritinin D.F. Porazhenie serdca pri hronicheskoy alkogol`noy intoksikacii. Vestnik novyh medicinskih tehnologiy. 2003; 4: 19–20. [Erokhin Yu.A., Chritin D.F. Cardiac involvement in chronic alcohol intoxication. Vestnik novyh medicinskih tehnologij. 2003; 4: 19–20 (in Russian)]
  31. Seredenin S.B., Voronin M.A. Neyroreceptornye mehanizmy deystviya afobazola. E`ksperim. i klin. farmakologiya. 2009; 72 (1): 3–11. [Seredenin S.B., Voronin M.A. Neuroreceptor mechanisms involved in the action of afobazole. Jeksperimental’naja i klinicheskaja farmakologija. 2009; 72 (1): 3–11 (in Russian)]
  32. Bhuiyan M.S., Fukunaga K. Targeting sigma-1 receptor signaling by endogenous ligands for cardioprotection. Expert Opin. Ther. Targets. 2011; 15 (2): 145–55.
  33. Cobos E.J., Entrena J.M., Nieto F.R., Cendán C.M., Del Pozo E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr. Neuropharmacol. 2008; 6 (4): 344–66.
  34. Wu Z., Bowen W.D. Role sigma-1 receptor C-terminal segment in inositol 1,4,5-triphosphate receptor activation: constitutive enhancementt of calcium signaling in MCF-7 tumor cells. J. Biol. Chem. 2008; 283 (42): 28198–215.
  35. Tagashira H., Bhuiyan M.S., Fukunada K. Divers regulation of IP3 and ryanodine receptors by pentazocine through σ1-receptor in cardiomyocytes. Am. J. Physiol. Heart Physiol. 2013; 305 (8): H1201–H12.
  36. Zhang X., Li S.Y., Brown R.A., Ren J. Ethanol and acetaldehyde in alcoholic cardiomyopathy: from bad toungly en route to oxidative stress. Alcohol. 2004; 32 (3): 175–86.
  37. Ren J., Wold L.E. Mechanisms of alcoholic heart disease. Ther. Adv. Cardiovasc. Dis. 2008; 2 (6): 497–506.
  38. Tagashira H., Bhuiyan S., Shioda N., Hasegawa H., Kanai H., Fukunaga K. Sigma1-receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice. Am.J. Physiol. Heart Circ. Physiol. 2010; 299 (5): H1535–H45.
  39. Kourrich S., Su T.P., Bonci A. The sigma-1 receptor: roles in neuronal plasticity and disease. Trends Neurosci. 2012; 35 (12): 762–71.
  40. Marriott K.S., Prasad M., Thapliyal V., Bose H.S. σ-1 receptor at the mitochondrial-associated endoplasmatic reticulum membrane is responsible for mitochondrial metabolic regulation. J. Pharmacol. Exp. Ther. 2012; 343 (3): 578–86.
  41. Hayashi T., Rizzuto R., Hajnoczky G., Su T.P. MAM: more than just a housekeeper. Trends Cell. Biol. 2009; 19 (2): 81–8.
  42. Hayashi T., Su T.P. Cholesterol at the endoplasmatic reticulum: roles of the sigma-1 receptor chaperone and implications thereof in human diseases. Subcell. Biochem. 2010; 51: 381–98.
  43. Su T.P., Hayashi T., Maurice T., Buch S., Ruoho A.E. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol. Sci. 2010; 31 (12): 557–66.
  44. Anelli T., Bergamelli L., Margittai E., Rimessi A., Fagioli C., Malgaroli A., Pinton P., Ripamonti M., Rizzuto R., Sitia R. Ero1b regulates Ca(2+) fluxes at the endoplasmatic reticulum-mitochondria interface (MAM). Antioxid. Redox. Signal. 2012; 16 (10): 1077–87.
  45. Joseph S.K., Hajnoczky G. IP3 receptors in cell survival and apoptosis: Ca2+ release and beyond. Apoptosis. 2007; 12 (5): 951–68.
  46. Roy S.S., Hajnoczky G. Calcium, mitochondria and apoptosis studies by fluorescence measurements. Methods. 2008; 46 (3): 213–23.
  47. Verfaillie T., Rubio N., Garg A.D., Bultynck G., Rizzuto R., Decuypere J.P., Piette J., Linehan C., Gupta S., Samali A., Agostinis P. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ. 2012; 19 (11): 1880–91.
  48. Johannessen M., Ramachandran S., Riemer L. Ramos-Serrano A., Ruoho A.E., Jackson M.B. Voltage-gated sodium channel modulation by sigma-receptors in cardiac myocytes and heterologous system. Am. J. Physiol. Cell. Physiol. 2009; 296 (5): 1049–57.
  49. Zhang H., Cuevas J. σ Receptor activation blocks potassium channels and depresses neuroexcitability in rat intracardiac neurons. J. Pharmacol. Exp. Ther. 2005; 313 (3): 1387–96.
  50. Hayashi T., Maurce T., Su T.P. Ca(2+) signaling via sigma(1)-receptor: novel regulatory mechanism affecting intracellular Ca(2+) concentration. J. Pharmacol. Exp. Ther. 2000; 293 (3): 788–98.
  51. Seredenin S.B., Ignatov Yu.D., Vislobokov A.I., Mel`nikov K.N., Yarkova M.A. Vliyanie afobazola na transmembrannye ionnye toki neyrona mollyuska. E`ksperim. i klin. farmakol. 2005: 68 (5): 3–6. [Seredenin S.B., Ignatov Yu.D., Vislobokov A.I., Mel’nikov K.N., Yarkova M.A. The Afobazole’s influence on the transmembrane ion currents of shellfish neuron. Jeksperimental’naja i klinicheskaja farmakologija. 2005: 68 (5): 3–6 (in Russian)]
  52. Zhang H., Katnik C., Cuevas J. Sigma receptor activation inhibits voltage-gated sosdium channels in rat intracardiac ganglion neurons. Int. J. Pathophysiol. Pharmacol. 2010; 2 (1): 1–11.
  53. Shioda N., Ishikawa K., Tagashira H., Ishizuka T., Yawo H., Fukunaga K. Expression of a truncated form of the endoplasmic reticulum chaperone protein, σ1 receptor, promotes mitochondrial energy depletion and apoptosis. J. Biol. Chem. 2012; 287 (28): 23318–31.
  54. Tsai S.Y., Hayashi T., Mori T., Su T.P.Sigma-1 receptor chaperone and diseases. Cent. Nerv. Syst. Agents Med. Chem. 2009; 9 (3): 184–9.
  55. Li S.Y., Ren J. Cardiac overexpression of alcohol dehydrogenase exacerbates chronic ethanol ingestion-induced myocardial dysfunction and hypertrophy: role of insulin signaling and ER stress. J. Mol. Cell. Cardiol. 2008; 44 (6): 992–1001.
  56. Jing L., Jin C.M., Li S.S. Zhang F.M., Yuan L., Li W.M., Sang Y., Li S., Zhou L.J. Chronic alcohol intake-induced oxidative stress and apoptosis: role of CYP2E1 and calpain-1 in alcoholic cardiomyopathy. Mol. Cell. Biochem. 2012; 359 (1–2): 283–92.